Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

2.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

3.

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK.

Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10.

4.

Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive.

Fishman MN.

Transl Androl Urol. 2017 Oct;6(5):839-847. doi: 10.21037/tau.2017.08.02. Review.

5.

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.

Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, Jim HSL.

Cancer. 2018 Feb 1;124(3):499-506. doi: 10.1002/cncr.31024. Epub 2017 Oct 26.

6.

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.

Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN Jr.

Cancer. 2017 Dec 1;123(23):4566-4573. doi: 10.1002/cncr.30942. Epub 2017 Aug 22.

7.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

8.

Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.

Donovan KA, Gonzalez BD, Nelson AM, Fishman MN, Zachariah B, Jacobsen PB.

Psychooncology. 2018 Jan;27(1):316-324. doi: 10.1002/pon.4463. Epub 2017 Jun 27.

9.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.

Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE.

Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.

PMID:
28361451
10.

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma.

Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R.

J Vasc Interv Radiol. 2017 Feb;28(2):254-259. doi: 10.1016/j.jvir.2016.09.025. Epub 2016 Dec 7.

PMID:
27955832
11.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-Macdonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M.

Clin Cancer Res. 2016 Nov 15;22(22):5461-5471. doi: 10.1158/1078-0432.CCR-15-2839. Epub 2016 May 11.

12.

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.

Rini BI, Tomita Y, Melichar B, Ueda T, Grünwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E.

Clin Genitourin Cancer. 2016 Dec;14(6):499-503. doi: 10.1016/j.clgc.2016.04.005. Epub 2016 Apr 22.

PMID:
27236772
13.

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB.

Support Care Cancer. 2016 Oct;24(10):4159-66. doi: 10.1007/s00520-016-3241-z. Epub 2016 May 3.

14.

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.

Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ.

World J Urol. 2016 Nov;34(11):1567-1573. Epub 2016 Apr 12.

PMID:
27072536
15.

Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Gonzalez BD, Jim HSL, Small BJ, Sutton SK, Fishman MN, Zachariah B, Heysek RV, Jacobsen PB.

Support Care Cancer. 2016 May;24(5):2201-2207. doi: 10.1007/s00520-015-3016-y. Epub 2015 Nov 13.

16.

Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma.

Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM.

Can J Urol. 2015 Aug;22(4):7882-9.

PMID:
26267026
17.

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, Park JY, Spiess PE, Fishman MN, Jacobsen PB.

J Clin Oncol. 2015 Jun 20;33(18):2021-7. doi: 10.1200/JCO.2014.60.1963. Epub 2015 May 11.

18.

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.

Fishman MN, Tomshine J, Fulp WJ, Foreman PK.

PLoS One. 2015 Apr 1;10(4):e0120877. doi: 10.1371/journal.pone.0120877. eCollection 2015. Review.

19.

Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.

Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB.

J Urol. 2015 Sep;194(3):690-5. doi: 10.1016/j.juro.2015.03.026. Epub 2015 Mar 16.

20.

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.

Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.

Ann Oncol. 2015 Jul;26(7):1372-7. doi: 10.1093/annonc/mdv103. Epub 2015 Feb 20.

21.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E.

Lancet Oncol. 2013 Nov;14(12):1233-42. doi: 10.1016/S1470-2045(13)70464-9. Epub 2013 Oct 18. Erratum in: Lancet Oncol. 2014 Jun;15(7):e253.

22.

Targeted therapy of kidney cancer: keeping the art around the algorithms.

Fishman MN.

Cancer Control. 2013 Jul;20(3):222-32. Review.

PMID:
23811706
23.

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF.

Eur J Cancer. 2013 Sep;49(13):2841-50. doi: 10.1016/j.ejca.2013.04.019. Epub 2013 May 28.

24.

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.

Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.

Cancer Control. 2013 Jan;20(1):7-16. Review.

PMID:
23302902
25.

Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game.

Basanta D, Scott JG, Fishman MN, Ayala G, Hayward SW, Anderson AR.

Br J Cancer. 2012 Jan 3;106(1):174-81. doi: 10.1038/bjc.2011.517. Epub 2011 Dec 1.

26.

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.

Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC.

Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.

28.

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.

Rodriguez AR, Fishman MN.

Expert Opin Pharmacother. 2007 Dec;8(17):2979-90. Review.

PMID:
18001257
29.

Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2006 Jan 15;12(2):523-8.

30.

Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2005 May 1;11(9):3335-41.

31.

[Systemic organization of perceptive activity in children with different levels of mental development].

Fishman MN.

Fiziol Cheloveka. 2003 Nov-Dec;29(6):67-73. Russian. No abstract available.

PMID:
14730935
32.

Cell-based immune therapy for metastatic renal cancer.

Fishman MN, Antonia SJ.

Expert Rev Anticancer Ther. 2003 Dec;3(6):837-49. Review.

PMID:
14686706
33.

[Functional status of the cortex and regulatory structures of the brainstem in children with impairments of speech development].

Fishman MN.

Fiziol Cheloveka. 2001 Sep-Oct;27(5):30-4. Russian. No abstract available.

PMID:
11680300
34.
35.

Considerations in the management of myeloma.

Fishman MN, Dalton WS.

Oncology (Williston Park). 2000 Nov;14(11A):72-81. Review.

PMID:
11195422
36.

[EEG-Expert automated diagnostic system].

Lukashevich IP, Machinskaia RI, Fishman MN.

Med Tekh. 1999 Nov-Dec;(6):29-34. Russian.

PMID:
10693124
37.

Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies.

Fishman MN, Sullivan DM.

Hematology. 2000;5(5):343-58. doi: 10.1080/10245332.2000.11746530.

PMID:
27420926
38.

[Neurophysiologic mechanisms of delay in psychic development in children. Structural analysis of EEG].

Lukashevich IP, Fishman MN, Machinskaia RI.

Fiziol Cheloveka. 1998 Jan-Feb;24(1):16-20. Russian. No abstract available.

PMID:
9567464
39.

[Dynamics of brain electrical activity in 5- to 8-year-old normal children and children with learning difficulties].

Machinskaia RI, Lukashevich IP, Fishman MN.

Fiziol Cheloveka. 1997 Sep-Oct;23(5):5-11. Russian. No abstract available.

PMID:
9410760
40.

Comparison of upper-extremity balance tasks and force platform testing in persons with hemiparesis.

Fishman MN, Colby LA, Sachs LA, Nichols DS.

Phys Ther. 1997 Oct;77(10):1052-62.

PMID:
9327820
41.

[Formation of brain electrical activity in mentally retarded 7- to 8-year-old children].

Fishman MN, Machinskaia RI, Lukashevich IP.

Fiziol Cheloveka. 1996 Jul-Aug;22(4):26-32. Russian. No abstract available.

PMID:
8964302
42.

[Role of regulatory structures of the brain stem in the functional maturation of the cerebral cortex in children aged 7-8].

Lukashevich IP, Machinskaia RI, Fishman MN.

Fiziol Cheloveka. 1996 Jan-Feb;22(1):63-8. Russian. No abstract available.

PMID:
8907454
43.
44.

[Structural organization of medical information as illustrated by diagnosis in child neurology].

Lukashevich IP, Machinskaia RI, Rudenskaia GE, Fishman MN, El'ner AM.

Med Tekh. 1995 Mar-Apr;(2):3-9. Russian.

PMID:
7791565
45.

[Diagnostics of brain functional state in young school children with learning problems].

Lukashevich IP, Machinskaia RI, Fishman MN.

Fiziol Cheloveka. 1994 Sep-Oct;20(5):34-45. Russian. No abstract available.

PMID:
7843546
46.

Distance distributions recovered from steady-state fluorescence measurements on thirteen donor-acceptor pairs with different Förster distances.

Wiczk W, Eis PS, Fishman MN, Johnson ML, Lakowicz JR.

J Fluoresc. 1991 Dec;1(4):273-86. doi: 10.1007/BF00865251.

PMID:
24243077
47.

[A neurophysiological analysis of interhemispheric interaction during visual perception in children].

Trush VD, Fishman MN.

Fiziol Cheloveka. 1991 Sep-Oct;17(5):91-7. Russian. No abstract available.

PMID:
1778381
48.

[Electrophysiologic analysis of the process of recognizing target and non-target stimuli in healthy and oligophrenic children].

Fishman MN, Trush VD.

Zh Vyssh Nerv Deiat Im I P Pavlova. 1987 Mar-Apr;37(2):226-33. Russian.

PMID:
3590965
49.

[Electrophysiological analysis of the perceptive activities of children with normal and retarded mental development].

Fishman MN, Trush VD.

Zh Vyssh Nerv Deiat Im I P Pavlova. 1986 Jan-Feb;36(1):20-7. Russian.

PMID:
3705761
50.

Spectral correlation analysis of the EEG in normal and mentally retarded children.

Fishman MN, Trush VD, Markovskaya IF.

Hum Physiol. 1983 Jan-Feb;9(1):43-9. No abstract available.

PMID:
6654355

Supplemental Content

Loading ...
Support Center